Publications by authors named "A Adrovic"
Transitional care is essential to maintain the continuity of care in younger patients with rheumatic diseases. In this study, we aimed to assess the transition readiness of rheumatology patients who had already transferred from pediatric to adult care using a questionnaire. We included young adult rheumatology patients who had already transferred to adult rheumatology care.
View Article and Find Full Text PDFObjective: Increased frequency of autoimmune thyroid disease, particularly Hashimoto's thyroiditis (HT) was reported several studies in the literature, in individuals with childhood-onset systemic lupus erythematosus (cSLE). Our study aimed to investigate the prevalence and contributing factors of thyroid dysfunction and HT among cSLE patients.
Methods: Thyroid function tests were obtained cross-sectionally from cSLE patients.
Familial Mediterranean Fever (FMF) is the most common monogenic autoinflammatory disease worldwide. In this retrospective cohort study, we aimed to assess the effects of various MEFV genotypes on the clinical characteristics of the patients, with a special focus on the joint involvement. In total, 782 patients with FMF were categorized into 3 groups according to the MEFV mutation; Group 1: Patients homozygous for M694V; Group 2: Patients carrying other pathogenic MEFV variants in exon 10 in homozygous or compound heterozygous states; and Group 3: FMF patients with other variants or without mutations.
View Article and Find Full Text PDFArticle Synopsis
- - The study focused on understanding clinical features, treatments, and outcomes of children with type I interferonopathy, aiming to identify long-term morbidity or mortality predictors.
- - Out of 40 patients, most were diagnosed with Aicardi-Goutières syndrome and exhibited significant central nervous system involvement, with a notable percentage experiencing permanent morbidity or death during follow-up.
- - The presence of intracranial calcification on MRI was identified as a key predictor of poor outcomes, highlighting important insights into this rare condition.
Background: To demonstrate the long-term safety profile of canakinumab over a nine-year period by documenting adverse events in patients with various pediatric rheumatic diseases.
Research Design And Methods: This retrospective observational study was conducted at the Pediatric Rheumatology Department of Istanbul University Cerrahpasa between 2015 and 2023. The analysis concerned individuals who had been administered canakinumab treatment for at least six months.